Revolution Medicines' daraxonrasib nearly doubles survival in pancreatic cancer trial

Data presented at the American Society of Clinical Oncology meeting showed that Revolution Medicines' experimental drug daraxonrasib significantly extended survival for patients with metastatic pancreatic cancer whose tumors carry a RAS G12 mutation.

In the Phase 3 study, median overall survival was 13.2 months for patients receiving daraxonrasib, compared with 6.6 months for those treated with standard chemotherapy. The survival benefit was similar when the entire trial population was considered, with chemotherapy patients living about 6.7 months.

Investigators called the findings unprecedented and suggest the therapy could quickly change clinical practice for this historically hard-to-treat disease.